UNC569 |
| Catalog No.GC18308 |
L'UNC569 est un inhibiteur puissant, réversible, compétitif pour l'ATP et actif par voie orale de Mer kinase avec une IC50 de 2,9 nM et un Ki de 4,3 nM. UNC569 inhibe également Axl et Tyro3 avec des IC50 de 37 nM et 48 nM, respectivement. L'UNC569 peut être utilisé pour la recherche sur la leucémie aiguë lymphoblastique (LAL) et les tumeurs tératoÏdes/rhabdoÏdes atypiques
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1350547-65-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
UNC569 is a potent inhibitor of the TAM family receptor tyrosine kinases Mer, Axl, and Tyro3 (IC50s = 2.9, 37, and 48 nM, respectively). It has antiproliferative activity in vitro against acute lymphoblastic leukemia (ALL) cells (IC50s = 0.5 and 1.2 μM for 697 and Jurkat cell lines, respectively) and inhibits Mer phosphorylation (IC50s = 141 and 193 nM in 697 and Jurkat cell lines, respectively). UNC569 activates Akt and ERK1/2 phosphorylation, induces apoptosis, and sensitizes ALL cells to etoposide and methotrexate . In vivo, UNC569 (4 μM) decreases tumor burden by 47.8% relative to vehicle controls in human MYC transgenic zebrafish. UNC569 (10 mg/kg) delays leukemia onset, reduces CNS infiltration, and prolongs survival of mice implanted with patient-derived Mer-expressing ALL primary cells.
Review for UNC569
Average Rating: 5 (Based on Reviews and 27 reference(s) in Google Scholar.)
Review for UNC569
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *